FzioMed raises $10 million:
This article was originally published in Clinica
FzioMed has raised $10 million through a private placement, enabling it to advance development of its Oxiplex adhesion barrier technology and accelerate European sales plans. Oxiplex is the San Luis Obispo, California-based company's patented polymer technology, which is aimed at a range of targeted medical applications and markets. Oxiplex was recently granted CE mark certification for use in spine, abdominal and pelvic surgery.
You may also be interested in...
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.